Cancer Care Ontario | Cancer Care Ontario

You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

362 Results

Guidelines and Advice

Recommendations Report Microwave Ablation and Cryoablation

May 2021

Guidelines and Advice

Preoperative Breast Magnetic Resonance Imaging

Status: Current
ID: GL 1-25
Version: N/A

Mar 2023

Guidelines and Advice

Enhancing the Delivery of Oncology Systemic Treatment in the Home and Community in Ontario Recommendations Report

Status: Current
Version: 1

Feb 2022

Guidelines and Advice

Role of Adjuvant Treatment in Resected Pancreatic Ductal Adenocarcinoma

Status: Current
ID: GL 2-33
Version: 2

Updated

Jun 2025

Guidelines and Advice

Systemic Therapy for Metastatic Urothelial Cancer: An Endorsement of a Portion of the European Association of Urology Guideline on Muscle-Invasive and Metastatic Bladder Cancer

Status: In-Review
ID: GL END 3-24

Aug 2022

Guidelines and Advice

Hepatitis B Virus Screening and Management for Patients Receiving Systemic Treatment

Status: Current

Sep 2022

Guidelines and Advice

Fluoropyrimidine Treatment in Patients with Dihydropyrimidine Dehydrogenase (DPD) Deficiency: Guidance for Clinicians

Status: Current
Version: 2

Updated

Sep 2025

Guidelines and Advice

Consensus-based organizational guideline for the planning and delivery of spine stereotactic body radiotherapy treatment in Ontario

Status: Current
ID: GL 21-6

Apr 2023

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines July to December 2022

Status: Current
ID: PET 2022-2

Jun 2023

Guidelines and Advice

Optimizing Ambulatory Systemic Treatment Models of Care

Status: Current
Version: 1

Jul 2023

Guidelines and Advice

An Endorsement of the 2022 NCCN Guideline on Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

Status: Current
ID: GL-END-C50-35

Aug 2023

Guidelines and Advice

Ontario Health (Cancer Care Ontario) Endorsement of ASCO Rapid Recommendation on 177Lutetium-Prostate-Specific Membrane Antigen-617 (PSMA-617) for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Status: Current
ID: GL-END 3-25

Nov 2023

Pages